163 related articles for article (PubMed ID: 19812445)
1. Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
Abel S; Davis JD; Ridgway CE; Hamlin JC; Vourvahis M
Antivir Ther; 2009; 14(6):831-7. PubMed ID: 19812445
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Taylor-Worth RJ; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):27-37. PubMed ID: 18333863
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
Abel S; van der Ryst E; Rosario MC; Ridgway CE; Medhurst CG; Taylor-Worth RJ; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):5-18. PubMed ID: 18333861
[TBL] [Abstract][Full Text] [Related]
5. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
[TBL] [Abstract][Full Text] [Related]
6. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.
Winters MA; Van Rompay KK; Kashuba AD; Shulman NS; Holodniy M
Antimicrob Agents Chemother; 2010 Oct; 54(10):4059-63. PubMed ID: 20696881
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
[TBL] [Abstract][Full Text] [Related]
9. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Lieberman-Blum SS; Fung HB; Bandres JC
Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
[TBL] [Abstract][Full Text] [Related]
10. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
Dumond JB; Patterson KB; Pecha AL; Werner RE; Andrews E; Damle B; Tressler R; Worsley J; Kashuba AD
J Acquir Immune Defic Syndr; 2009 Aug; 51(5):546-53. PubMed ID: 19546811
[TBL] [Abstract][Full Text] [Related]
11. The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Russell D; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):47-53. PubMed ID: 18333865
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc: pharmacokinetics and drug interactions.
Abel S; Back DJ; Vourvahis M
Antivir Ther; 2009; 14(5):607-18. PubMed ID: 19704163
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.
Vourvahis M; Plotka A; Mendes da Costa L; Fang A; Heera J
Antimicrob Agents Chemother; 2013 Dec; 57(12):6158-64. PubMed ID: 24080663
[TBL] [Abstract][Full Text] [Related]
14. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
[TBL] [Abstract][Full Text] [Related]
16. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
17. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
18. CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study.
Garvey L; Nelson M; Latch N; Erlwein OW; Allsop JM; Mitchell A; Kaye S; Watson V; Back D; Taylor-Robinson SD; Winston A
J Antimicrob Chemother; 2012 Jan; 67(1):206-12. PubMed ID: 21987241
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc.
Ramanathan S; Abel S; Tweedy S; West S; Hui J; Kearney BP
J Acquir Immune Defic Syndr; 2010 Feb; 53(2):209-14. PubMed ID: 19851115
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
